search
Back to results

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Nebivolol
Sponsored by
Mylan Bertek Pharmaceuticals
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Nebivolol, Hypertension, Beta-Blocker

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: To enter the long-term treatment phase, patients must have successfully completed NEB 202, NEB 302, or NEB 305. To enter the 4-week follow-up phase, patients must have completed NEB-306 (extension phase) and received only nebivolol monotherapy treatment during NEB 306. Exclusion Criteria: Secondary hypertension myocardial infarction or stroke contraindications to beta-blocker therapy

Sites / Locations

  • Mylan Pharmaceuticals Inc.

Outcomes

Primary Outcome Measures

The change in average sitting diastolic blood pressure measured at trough drug plasma level at the end of the extension phase compared to baseline of NEB 202, NEB 302 or NEB 305.

Secondary Outcome Measures

Change in the average
- sitting systolic blood pressure
- supine and standing systolic and diastolic blood pressure
- response rate of treatment groups
- AEs
- ECGs
- laboratory parameters
- heart rate

Full Information

First Posted
September 13, 2005
Last Updated
December 15, 2005
Sponsor
Mylan Bertek Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00200499
Brief Title
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
Official Title
A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
March 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2003 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Mylan Bertek Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary
The study was conducted to determine the long-term safety and efficacy of nebivolol in patients with mild to moderate hypertension. This was an extension of the Phase III dose ranging studies NEB 202, 302 and 305. Nebivolol was studied as monotherapy and in conjunction with add-on antihypertensive therapy.
Detailed Description
This was an international, multicenter parallel group, 9-month extension study with a 4-week follow-up phase to evaluate the long-term safety and efficacy of nebivolol administered orally once daily in patients with mild to moderate hypertension (defined as an average sitting diastolic blood pressure greater then or equal to 95 mmHg and less then or equal to 109 mmHg when untreated, based on entry into NEB 202, NEB 302 or NEB 305). Patients were permitted protocol-defined concomitant use of diuretic or calcium antagonist. After successful completion of one of the 3-month efficacy "feeder" studies, patients were eligible to continue nebivolol treatment in this 9-month extension study. Patients who completed the extension phase and received only nebivolol monotherapy during the extension phase were eligible to enter the 1-month follow-up phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Nebivolol, Hypertension, Beta-Blocker

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
Double
Allocation
Randomized
Enrollment
845 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Nebivolol
Primary Outcome Measure Information:
Title
The change in average sitting diastolic blood pressure measured at trough drug plasma level at the end of the extension phase compared to baseline of NEB 202, NEB 302 or NEB 305.
Secondary Outcome Measure Information:
Title
Change in the average
Title
- sitting systolic blood pressure
Title
- supine and standing systolic and diastolic blood pressure
Title
- response rate of treatment groups
Title
- AEs
Title
- ECGs
Title
- laboratory parameters
Title
- heart rate

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: To enter the long-term treatment phase, patients must have successfully completed NEB 202, NEB 302, or NEB 305. To enter the 4-week follow-up phase, patients must have completed NEB-306 (extension phase) and received only nebivolol monotherapy treatment during NEB 306. Exclusion Criteria: Secondary hypertension myocardial infarction or stroke contraindications to beta-blocker therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Betty S. Riggs, MD, MBA
Organizational Affiliation
Mylan Pharmaceuticals Inc
Official's Role
Study Director
Facility Information:
Facility Name
Mylan Pharmaceuticals Inc.
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26505
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

We'll reach out to this number within 24 hrs